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Alzheimer's disease (AD), a progressive neurodegenerative disorder of the aged brain with no known
cause or cures, has become a major medical and social problem for industrialized countries. Cerebral
deposition of amyloid-β peptide (Aβ) is a critical feature of AD. The use of medicinal plants as an al-
ternative form of prevention, or even as a possible treatment of AD, is therefore interesting areas of
research. Sesquiterpene lactones and a sesquiterpene alcohol are compounds found in H. brasiliense that
have several anti-oxidative and anti-inﬂammatory effects. In the present study, we investigated whether
these compounds have neuroprotective effects in an amyloid-β peptide-induced Alzheimer's disease
mouse model. Mice were injected with Aβ1-42 peptide intracerebroventricularly and were subsequently
injected (i.c.v.) with 1 mg/site of IGM-A (15-acetoxy-isogermafurenolide), IGM-H (15-hydroxy-iso-
germafurenolide), PDA (Podoandin), EHP (1,2-epoxy-10α-hydroxy-podoandin), HDS (13-hydroxy-8,9-
dehydroshizukanolide), and ARD (aromadendrane-4β,10α-diol). Seven days after treatments the animals
had their memory tested in the inhibitory avoidance. After the behavioral testing of animals the brains
were removed and subjected to biochemical tests for oxidative stress. The results showed that ARD, HDS
and PDA signiﬁcantly ameliorated the Aβ1-42 peptide-induced memory impairment in the passive
avoidance task (Po0.05). In addition, GSH activity was increased while the TBARS levels were decreased
by treatment with these compounds. These results suggest that these compounds inhibit the cognitive
deﬁcit of animals induced peptide amyloid and may be potential candidates for Alzheimer's disease
therapy.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is a progressive age-related neuro-
degenerative disorder and is the most common form of dementia
among the elderly, generally diagnosed in individuals over the age
of 65 years. The main pathological hallmarks of AD are the accu-
mulation of amyloid plaques, or senile plaques, containing extra-
cellular deposits of amyloid-β peptide (Aβ) and the presence of
intraneuronal neuroﬁbrillary tangles (NFTs), which result from
hyperphosphorylated τ-protein (Konrath et al., 2013). The oxida-
tion of lipids, proteins, and nucleic acids in neurons is also aosia, CIF/CCS/UFSC, Campus
Brazil.
vatti).common pathological feature of AD (Chen and Zhong, 2014).
The etiology of AD is still unknown, but several factors have
been suggested that appear to reduce the incidence of the disease.
Three main approaches have been taken: the ﬁrst involves the re-
establishment of neurotransmitters levels, with the inhibition of
cholinesterases, acetylcholinesterase (AChE), butyrylcholinester-
ase (BChE), and also monoamine oxidase (MAO) enzymes. The
second one concerns neuroprotection where oxidative stress is
considered to be an early event in the pathological cascade for the
disease, suggesting the potential use of antioxidants to limit the
effects of free radicals on nerve cells. The third approach deals
with speciﬁc aspects related to AD, including the decrease in the
production or aggregation of Aβ peptide, and inhibition of γ and β-
secretase enzymes which play a critical role in the amyloidogenic
and t-protein pathways, among others (Konrath et al., 2013).
The current drug therapy used is palliative and drugs exhibit
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and can hardly prevent, halt, or reverse the disease. Exploration of
natural active ingredients from medicinal herbs for treatment of
AD has attracted substantial attention worldwide. Thus far, drugs
including galantamine and huperzine which were originated from
traditional Chinese herbs have been developed and used in clinics
to treat mild to moderate AD (Gao et al., 2013).
Hedyosmum brasiliense Miq. is identiﬁed in folk medicine as
“Cidrão”, “Âmbar vegetal”, “Canela-cânfora” “Chá-de-bugre”,
“Hortelã-do-brejo” among others. Although it is widely used as a
sedative, hypnotic, antidepressant, stomachic and for aphrodisiac
purposes (Di Stasi et al., 1988; Reitz, 1965), studies which seek to
validate its phytochemical composition and also to demonstrate its
pharmacological effects are few. The neurochemical properties of
the ethanol leaf extract and its fractions showed sedative, hyp-
notic, anxiolytic and antidepressant effects, (Tolardo et al., 2010)
and the antidepressant effect of the isolated sesquiterpene lac-
tones 13-hydroxy-8,9-dehydroshizukanolide (or onoseriolide) and
podoandin have recently been studied by this group (Goncalves
et al., 2012). The plant itself is not used in folk medicine in cog-
nitive deﬁcits, but the presence of lactones as a component in their
chemical constitution sparked interest for research in this area.
Has been reported that these compounds inhibit oxidative stress
(Gach et al., 2015) In addition, triterpene lactones are acet-
ylcholinesterase inhibitors (Hajimehdipoor et al., 2014). Since an-
ticholinesterase agents are used in the treatment of the Alzhei-
mer's disease, and that oxidative stress may be involved in neu-
rodegenerative processes, the present work describes the effects of
sesquiterpene lactones and of a sesquiterpene alcohol from the
leaves of H. brasiliense. These compounds were tested against
cognitive deﬁcit induced by the amyloid peptide Aβ1-42, with the
purpose of identifying their anti-Alzheimer potential.2. Materials and methods
2.1. Plant material
Aerial parts of H. brasiliense Miq (Chloranthaceae) were col-
lected in the municipal area of Antonio Carlos, Santa Catarina,
Brazil in October 2009. It was identiﬁed by the botanist Dr. Ademir
Reis and a voucher specimen (no. 2031) was deposited at the Ly-
man Bradford Smith Herbarium (UNIVALI, Itajaí – Santa Catarina).
2.2. Isolation of compounds
Fresh leaves of H. brasiliense (5 kg) were extracted, at room
temperature, with ethanol (95%) for 15 days. The solvent was re-
moved under reduced pressure and used to re-extract the plant
material. The resulting crude extracts were combined (190 g) and
stored in a desiccator in vacuo, to remove any solvent residue. The
extract was dissolved in water and partitioned with solvents of
increasing polarity, yielding n-hexane (16 g), dichloromethane
(CH2Cl2, 4 g), and ethyl acetate (EtOAc, 13 g) fractions, as well as a
residual aqueous fraction. All fractions were stored at 18 °C.
The n-hexane fraction was subjected to ﬂash silica gel column
chromatography (CC, 240–400 mesh), eluting with a gradient of 0–
70% CH2Cl2 in n-hexane (200 ml) followed by 0–70% EtOAc in
CH2Cl2 (200 ml), yielding eight sub-fractions (A–H).
Sub-fraction B was re-crystallized to produce PDA (300 mg),
which was identiﬁed as podoandin by comparison with previously
reported NMR spectroscopic data (Blay et al., 2000; Kubo et al.,
1992). HDS (40 mg), crystallized spontaneously from sub-fraction
C and was identiﬁed as onoseriolide by comparing its NMR spec-
troscopic data with those reported in the literature (Trentin et al.,
1999). Sub-fraction F was submitted to silica gel CC with elutingwith n-hexane–CH2Cl2–acetone (4:5:1), yielding IGM-Awhich was
elucidated as 15-acetoxy-isogermafurenolide (35 mg) (Amoah
et al., 2013). 3 g of the dichloromethane fraction was subjected to
ﬂash silica gel (240–400 mesh) column chromatography (CC) and
eluted in a gradient system consisting of increasing concentrations
of CH2Cl2 in n-hexane (0–70%, 200 ml) followed by ethyl acetate in
dichloromethane (0–70%, 200 ml) which produced sub-fractions
(I-P). Sub-fraction M was puriﬁed on silica gel CC, eluting with 9:1
to 3:7 acetone in n-hexane, which yielded 11 new sub-fractions
(M1–M11). Sub-fraction M8 (111 mg) was subjected to further si-
lica gel CC, eluting with 9:1 to 3:7 EtOAc in dichloromethane,
which gave IGM-H, elucidated as 15-hydroxy-isogermafurenolide
(15 mg) (Amoah et al., 2013). Subfraction P was also subjected to
CC on silica which led to the isolation of EHP and ARD and were
identiﬁed as sesquiterpenoids 1,2-epoxy-10α-hydroxy-podoandin
(Amoah et al., 2013) and aromadendrane-4β,10α-diol (Moreira
et al., 2003) respectively. The elucidation of these substances was
achieved by 1D, 2D NMR and in comparison with published data,
as cited above.
2.3. Chemicals and reagents
All drugs were freshly prepared before use. 5,5′-Dithiobis (2-
nitro benzoic acid) DTNB, bovine serum albumin (BSA), and re-
duced glutathione (GSH) standard were purchased from SIGMA
(EUA). Thiobarbituric acid and Aβ1-42 were obtained from (De-
moleris/SA, BRAZIL)
2.4. Animals
Experiments were conducted using 3-month-old male Swiss
albino mice weighing 25–35 g, obtained from central bioterium of
UNIVALI. They were kept in groups of 10 animals per cage
(413416 cm) and maintained in a room under controlled
temperature (2371 °C). They were subjected to a 12 h light cycle
(lights on 7:00 a.m.) with free access to food and water. All pro-
cedures used in the present study complied with the guidelines on
animal care of the local Ethics Committee on the Use of Animals
which follows the NIH publication “Principles of laboratory animal
care”. The experimental protocols were submitted to the ethical
committee for animal use CEUA / UNIVALI being approved with
the number CEUA/21/12.
2.5. Amyloid- β peptide administration
Aβ1–42 (Tocris, MO, USA) (Bachem, CA, USA) was prepared as
stock solution at a concentration 0.6 μg/μl in sterile 0.1 M phos-
phate-buffered saline (PBS) (pH 7.4), and aliquots were stored at
20 °C. Aβ1–42 was aggregated by incubation in sterile distilled
water at 37 °C for 4 days before use as described previously
(Prediger et al., 2007) Aβ1–42 (400 pmol/mouse), or control solu-
tion (PBS) were administered by intracerebroventricular (i.c.v.)
route using a microsyringe with a 28-gauge stainless-steel needle
3.0 mm long (Hamiltons) according to the procedure previously
described by Piermartiri et al. (2010). After counted anesthesia,
each animal was immobilized carefully and in brief, the needle
was inserted unilaterally 1 mm to the right of the midline point
equidistant from each eye, at an equal distance between the eyes
and the ears and perpendicular to the plane of the skull. The in-
jection volume (3 μl) of Aβ1–42, was delivered gradually. After
5 min after application of the peptide, microsyringes were chan-
ged and the compounds were applied in the same manner as the
peptide. Mice exhibited normal behavior recovery from anesthe-
sia. The injection placement or needle track was visible and was
veriﬁed at the time of dissection. The present Aβ1–42 dose is
comparable to that of previous literature on the use of Aβ1–42
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2.6. Experimental design
The behavioral tasks studies were performed 7 days after i.c.v.
administration of Aβ1–42 (400 pmol/mouse), compounds, vehicle
(PBS/0.5 ml) or galantamine (0.1 mg/kg, s.c.) as follows illustrative
scheme:
2.6.1. Open ﬁeld test
To verify the effects of i.c.v. treatment with compounds on lo-
comotor activity, the animals were placed for 5 min in the open
ﬁeld arena. The apparatus, made of wood covered with im-
permeable Formicas, had a black ﬂoor of 30 cm30 cm (divided
by white lines into nine squares of 10 cm 10 cm) and transpar-
ent walls, 15 cm high. The experiments were conducted in a
sound-attenuated room under low-intensity light (12 lx). Each
mouse was placed in the centre of the open ﬁeld and the numbers
of squares crossed (crossings) and rearings were registered (To-
lardo et al., 2010).
2.6.2. Elevated plus-maze test
In order to determine if compounds might have affected mo-
bility, locomotion or pro- or anti-conﬂict behaviours, animals were
also submitted to an elevated plus-maze (EPM) (Pellow et al.,
1985). The EPM is made of wood, in the form of a Greek cross with
two open arms (3050.2 cm) and two closed (30155 cm),
the arms are connected by a central open area (55 cm). The EPM
is raised to a height of 45 cm above the ﬂoor. Animals were al-
lowed to explore the apparatus, which is used to measure pro- or
anti-conﬂict behaviours as animal models of anxiety (Pellow et al.,
1985; Tolardo et al., 2010). After 5 min of i.c.v. administration of
the compounds (1 mg/0.5 ml/side,) or vehicle, each animal was
placed in the centre of the apparatus, facing one of the enclosed
arms. The total number of entries into the four arms, the number
of entries and the time spent into the open arms were recorded
over a 5 min session. After each trial, the open ﬁeld apparatus was
wiped clean with ethanol (10%) solution.
2.6.3. Step-Down inhibitory avoidance test.
The animals were submitted to one trial step-down inhibitory
avoidance and this test was performed according to Izquierdo et al.
(2004). The animals were gently placed on a 2.5-cm high, 7.0-cm
wide, 25.0-cm long Formicas platform at the left side of a
502525-cm apparatus, ﬂoor of which was a series of parallel
0.1-cm caliber stainless-steel bars spaced 1.0 cm apart. A 15 W
lamp at the top center of the device illuminates the apparatus. In
the training session, latency to step down placing the four paws on
the grid was measured, immediately followed by a 3.0-s, 0.4-mA
foot-shock. Retention test sessions, procedurally identical to the
training session, were carried out 24 h after training, without foot-
shock and with step-down latency limited to 180 s, i.e., test session
values higher than 180 s were counted as 180 s. Retention test
performances at 24 h were taken as measures of retention of long-
term memory.
2.7. Biochemical determinations
Animals were killed by cervical dislocation, brains were re-
moved and homogenized in phosphate buffer (pH¼7.4). The
homogenates were than centrifuged at 3000 g for 15 min. The
supernatant of homogenates were used for biochemical estima-
tions using the methods described below.
2.7.1. Estimation of brain thiobarbituric acid reactive species(TBARS) level
Lipid peroxidation is measured by the production of mal-
ondialdehyde (MDA), achieved spectrophotometrically by the
method of Ohkawa et al. (1979) using 1,1,3,3-tetraethoxypropane
as standard and expressed as nmol per mg protein. The reagents
acetic acid 1.5 ml (20%) pH 3.5, 1.5 ml thiobarbituric acid (0.8%)
and 0.2 ml sodium dodecyl sulfate (8.1%) were added to 0.1 ml of
the processed sample. This mixture was then heated at 100 °C for
60 min, cooled under tap water and 5 ml of n-butanol:-pyridine
(15:1% v/v) plus 1 ml of distilled water was added. The mixture
was shaken vigorously on vortex. After centrifugation at 4000 g for
10 min, the organic layer was withdrawn and absorbance mea-
sured at 532 nm.
2.7.2. Estimation of brain reduced glutathione (GSH) level
The whole brain GSH level was measured by the method of
(Beutler et al., 1963) with slight modiﬁcations. The absorbance was
measured at 412 nm (DU 640B spectrophotometer, Beckman
Coulter Inc., CA, USA). Different concentration of the GSH standard
was processed similarly to prepare a standard curve (5–50 μg).
Results were expressed as nmol of GSH/mg of protein.
2.8. Statistical analysis
For tests as open ﬁeld and plus maze, the values are expressed
as mean7S.E.M. Statistical signiﬁcance was determined by ANO-
VA followed by Newman-Keuls post-hoc test. Values with Po0.05
were considered signiﬁcant. For inhibitory avoidance task, because
of the ceiling of 180 s imposed on test session measures, non-
parametric statistics were used. Data are expressed as median
(interquartile range). The two-tailed Mann-Whitney U-test eval-
uated test session differences from controls. The Wilcoxon test
evaluated differences between training and test session perfor-
mances in each group.3. Results
3.1. Effects of compounds on the behavioral parameters in the open
ﬁeld test
The tested compounds are presented in the Fig. 1. The Table 1
shows that none of these compounds and galantamine when ad-
ministered in animals produced changes in behavioral parameters
like crossings and rearing's when compared to the control group
(P40.05). These results indicate that there were no sedative ef-
fects in mice, as assessed by the open ﬁeld apparatus (Table 1).
3.2. Effects of compounds on the behavioral parameters in the plus
maze test
Table 2 shows that the number of entries and the time spent by
the animals in the open arms were not altered by treatment with
the compounds tested and galantamine when compared with the
control group (P40.05). Behavioral changes were also not ob-
served in the frequency of entries and time spent in the closed
arms (P40.05). These results also demonstrated that treatment of
animals with the compounds and galantamine did not alter the
behavioral parameters related to anxiety.
3.3. Effects of compounds on aversive memory of Swiss mice in the
inhibitory avoidance test
Results for the inhibitory avoidance test are displayed in Fig. 2.
In the test session, groups that received the amyloid peptide Aβ1–
42 (400 pmol/mouse) and were treated with ARD, HDS and PDA
Fig. 1. Structures of substances evaluated in Alzheimer model and their respective carbonskeletons. IGM-A-15-acetoxy-isogermafurenolide, IGM-H – 15-hydroxy-iso-
germafurenolide, PDA – Podoandin, EHP-1,2-epoxy-10α-hydroxy-podoandin, HDS – onoseriolide, ARD-aromadendrane-4β,10α-diol.
Table 1
Effect of the administration of compounds (1 mg/mouse, i.c.v.) and galantamine
(0.1 mg/kg, s.c.) on animal behavior in the Open Field test. Data are presented as
mean7S.E.M. N¼8–10 per group. Does not differ from vehicle.
Treatments Crossing Rearing
Vehicle 112.273.18 48.1072.20
ARD 109.675.44 53.6071.62
HDS 120.173.86 55.1072.72
IGM-H 109.575.79 51.1071.86
IGM-A 114.274.72 61.2072.22
PDA 109.774.38 57.9072.19
EHP 110.274.33 57.707 1.22
Galantamine 106.473.31 50.207 6.33
Table 2
Effect of the administration of compounds (1 mg/mouse, i.c.v.) and galantamine
(1 mg/mouse, i.c.v.) on animal behavior in the plus maze test. Data are presented as
mean7S.E.M. N¼8–10 per group. Does not differ from vehicle.
Treatments % Frequency
entry into the
open arms
%Frequency
entry into the
closed arms
% Time of per-
manence in
the open arms
% Time of per-
manence in
the closed
arms
Vehicle 34.5172.12 76.9072.10 42.5071.52 61.2372.15
ARD 36.3574.21 83.0073.70 48.507 1.56 64.5373.55
HDS 44.1173.17 81.0072.17 43.507 1.23 67.2274.52
IGM-H 35.5272.23 79.0071.27 42.507 1.57 60.2971.25
IGM-A 45.1274.23 81.4073.70 47.507 2.56 65.4571.65
PDA 38.5672.63 69.1472.6 47.307 3.50 57.5674.15
EHP 37.5273.23 63.2974.65 42.3473.50 64.5371.45
Galantamine 37.1575.31 69.1171.32 42.347 2.15 61.4573.51
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memory retention in test session when compared with animals
treated with vehicle (control), an effect which was statistically
signiﬁcant. These results show that these compounds reverse the
cognitive deﬁcits induced by the amyloid peptide Aβ1–42. Inaddition, the Fig. 2 also shows that SHAM animals (who did not
receive treatment with amyloid peptide) had higher memory re-
tention in test session when compared with animals treated with
Fig. 2. (A) The representation scheme of the experiment of inhibitory avoidance.
(B) Effect of intracerebroventricular infusion of vehicle (PBS/0.5 ml) and com-
pounds: IGM-A, IGM-H, PDA, EHP, HDS, ARD (1 mg/mouse, i.c.v.) that received
amyloid peptide Aβ1–42 (400 pmol/mouse, i.c.v) on inhibitory avoidance memory
test sessions. Bars represent median (interquartile range) of step-down latencies
during a memory retention test session carried out 24 h after training. N 8–10 per
group; * Po0.05 and ** Po0.001, comparing with vehicle in Dunn’s comparison
after Kruskal–Wallis test, #Po0.05 comparing the treatments in the test sessions.
SHAM¼group of animals that received no treatment with Aβ1–42.
Fig. 3. Effect of intracerebroventricular infusion of vehicle (PBS/0.5 ml), com-
pounds: IGM-A, IGM-H, PDA, EHP, HDS, ARD (1 mg/mouse, i.c.v.) and galantamine
(0.1 mg/kg, s.c.) that received amyloid peptide Aβ1–42 (400 pmol/mouse, i.c.v.) on
TBARS content (A) and GSH activity (B). Bars represent means7S.E.M. N 8-10 per
group; **Po0.001, comparing with SHAM and, ##Po0.001 or ##Po0.0001
comparing with vehicle. Aβ1–42 infusion leads to signiﬁcant alterations in the ac-
tivities of antioxidant enzymes (GHS), and TBARS in hippocampus. Pretreatment of
ARD, HDS, PDA and galantamine signiﬁcantly increased the activity of this enzyme
and decreased of lipid peroxidation. SHAM¼group of animals that received no
treatment with Aβ1–42.
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IGM-H, IGM-A and EHP, no signiﬁcant results regarding the re-
versal of cognitive deﬁcits induced by Aβ1–42 were observed.
3.4. Effect on brain oxidative stress levels
I.c.v. Aβ1–42 markedly enhanced oxidative stress due to the
increase of the TBARS (Fig. 3 A) and the reduction of the GSH levels
in the brain (Fig. 3 B) when compared to the control (SHAM)
group. The compounds IGM-H, IGM-A and EHP (0.1 mg/kg/day, i.
p.) produced signiﬁcant increase on TBARS levels. However, sig-
niﬁcant reduction in oxidative stress by enhanced GSH level was
observed with ARD, HDS, PDA and galantamine (0.1 mg/kg/day, s.
c.) in Aβ1–42 mice.4. Discussion
An immense health burden has been imposed by AD, for which
there is no prevention and no disease-modifying agents which
have been approved so far. AD is a progressive neurodegenerative
disorder characterized, at least in part, by abnormal accumulation
of amyloid-β peptide (Aβ) in the brain (Huang and Mucke, 2012).
The accumulated Aβ is believed to play an important role in the
pathogenesis of AD (Maltsev et al., 2011) hence, an important
target for prevention and treatment of AD (Lemere and Masliah,
2010). In AD treatment, acetylcholinesterase inhibitors are among
the most extensively studied drugs, which have shown to sig-
niﬁcantly improve cognitive function in AD. However, these drugs
are known to have limitations for clinical use due to their short-
half-lives and/or unfavorable adverse effects (Gongadze et al.,
2008; Singh et al., 2012). Thus, the study of new compounds withanti-Alzheimer potential is fundamental.
Essa et al. (2012) and Howes and Houghton (2012) proved that
herbal medicines containing phytochemicals can modify brain
aging. Various factors which may contribute to the impairment of
learning and memory change in the brain neurotransmitter levels
include cholinergic and monoamines and free radicals in the brain
region.
Galantamine, unlike the other anticholinesterases, is an alka-
loid obtained from natural sources. It was ﬁrst isolated from Ga-
lanthus nivalis L., which belongs to the Amaryllidaceae family. This
product was ﬁrst marketed in 2001 and is a long-acting, relatively
selective AChE inhibitor, with less BChE inhibitory activity and
some gastrointestinal adverse effects described. Galantamine also
improves cholinergic transmission by allosteric modulation of ni-
cotinic receptors and has been used to treat the symptoms of other
forms of dementia. It is currently isolated from daffodil bulbs
(Narcissus spp) by the pharmaceutical industry, which has en-
gendered an exponential interest in the isolation and character-
ization of alkaloids from Amaryllidaceae bulbs (e.g. lycorine,
homolycorine and hipeastrine), most of them having antic-
holinesterase activity. Besides, it also exhibits less toxicity than
other AChEIs like tacrine (Fang et al., 2014; Konrath et al., 2013).
Sesquiterpenoids are natural compounds with a 15-carbon
frame skeleton that are considered to be important for plants
protection and for humans, presenting many biological activities,
such as anti-inﬂammatory, antimicrobial, antitumor, and cytotoxic
properties (Chadwick et al., 2013; Chen et al., 2011). About 100
different skeleton types of sesquiterpenoids have been isolated
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liense, sesquiterpenoids with the elemane, guaiane and lindenane
carbon skeletons (Fig. 1) have been found. In this present work, the
results showed that only PDA and ARD (guaiane group), and HDS
(lindenanolide group) signiﬁcantly ameliorated the Aβ1-42 pep-
tide-induced memory impairment in the passive avoidance test.
Step-down inhibitory avoidance task is a classic task of memory
with a strong aversive component. This is a quick, easy to perform
model without the need for multiple training sessions (Alonso
et al., 2005). How quickly learned, the inhibitory avoidance allows
for the precise time after learning in which treatments affect
memory consolidation difﬁcult to discern in tasks that require
many procedures. In humans, this represent an inhibitory avoid-
ance constantly used and a necessary form of memory (Furini
et al., 2014) This model does not only depend on brain structures
such as the hippocampus, but others such as entorhinal cortex and
amygdala (Blank et al., 2014), all affected by the neurodegenerative
process in the Alzheimer's disease (Singh et al., 2014).
Another important aspect evaluated in this study was that
treatment of animals with these compounds produced no de-
tectable adverse effects such as increased or decreased locomotor
activity. These effects on the locomotor activity were investigated
using the open ﬁeld test to rule out the possibility that the effect of
the compounds in the animals subjected to the inhibitory avoid-
ance task could be a consequence of increased locomotor activity.
However, it should be emphasized that drugs that induce hy-
perlocomotion may give a “false” positive effect in this test,
whereas drugs that decrease locomotion may give a ‘false’ nega-
tive result (Tolardo et al., 2010). Similarly, treatment with the
compounds causes no detectable emotional changes in the model
of elevated plus-maze, which is frequently used to detect and
evaluate the anxiolytic/anxiogenic properties of drugs (Pellow and
SE, 1987).
In this present work, i.c.v. Aβ1–42 markedly produced cognitive
deﬁcits and abnormal biochemical alterations in the mice brain.
The oxidative stress is the state of imbalance between the level of
antioxidant defense mechanism and production of the free radi-
cals that favors potential brain damage. Brain tissue is particularly
susceptible to oxidative damage due to its high oxygen content,
low level of antioxidant protection, and high level of poly-
unsaturated fatty acids (Moreira et al., 2005). Therefore, it is be-
lieved that pharmacological modiﬁcation of oxidative damage is
one of the most promising strategies in the treatment of neuro-
degenerative diseases. Reactive oxygen species (ROS)-induced
damage to biomolecules (lipids, proteins, DNA and RNA) plays an
important role in the advancement of aging and age-related
neurodegenerative disorders such as AD (Liu et al., 2003). In vivo
studies have shown that rats showed AD-like behavioral and pa-
thological changes induced by injection of Aβ into the lateral
cerebral ventricle or hippocampus (Cheng et al., 2006; Nobakht
et al., 2011). However, the mechanisms underlying Aβ-mediated
neurotoxicity remain unclear. It is evidenced that Aβ can accu-
mulate in mitochondria and lead to enhanced reactive oxygen
species (ROS) generation and mitochondrial energy metabolism
impairment (Alikhani et al., 2011; Manczak et al., 2004). Reduced
GSH is the most abundant non-protein thiol, which buffers free
radicals in brain tissue (Dringen et al., 2000). The redox system of
glutathione consists of GSH and an array of functionally related
enzymes, of which GR is responsible for the regeneration of GSH,
whereas GPx works together with GSH in the decomposition of
H2O2 and other organic hydroperoxides. Consistent with previous
works, in the present study, Aβ142 caused a decrease in GSH le-
vels (Ding et al., 2013). A reduction in the levels of GSH may impair
H2O2 clearance and promote formation of OH, the most toxic
moiety to the brain, leading to more oxidant load and conse-
quently oxidative damage. In this study, the treatments of animalswith compounds ARD, HDS and PDA prevented this process which
may be the mechanism responsible for facilitating effects of in-
hibitory avoidance memory. Damage to myelin sheath by Aβ oxi-
dative stress may lead to cognitive dysfunction (Sims-Robinson
et al., 2013). In line with these studies, Aβ treated mice performed
poorly on inhibitory avoidance indicating impairment in their
learning abilities and memory capabilities. Furthermore, there was
a signiﬁcant rise in brain activity and oxidative stress levels (in-
dicated by an increase in TBARS and decrease in GSH levels) which
is consistent with earlier reports (Yin et al., 2014).
The majority of sesquiterpene lactones exert their biological
activities through a reaction called the Michael-type addition
where they react with cellular nucleophiles. The α,β-unsaturated
carbonyl, epoxy-, aldehyde-, and peroxy have been considered
potential reactive moieties (Merfort, 2011; Schmidt, 2006). How-
ever, other factors, such as lipophilicity, molecular geometry, and
chemical environment or the target sulfhydryl may also inﬂuence
the activity of the sesquiterpene lactones (Chaturvedi, 2011).
With regards to this work, it has been observed that the lactone
ring moiety may not be essential for the activity in the evaluated
model. Only three substances PDA, ARD and HDS exerted good
activities with PDA4ARD4HDS. It can further be observed that
ARD which is a sesquiterpene alcohol showed a better activity
than the sesquiterpene lactone HDS. Apparently the hydrophobic
and rigid moiety C1-C5 ring present in guaiane skeletons of PDA
and ARD (Fig. 1) are the most interactive part of the compounds,
since the elemane compounds IGM-H and IGM-A possess an open
chain in C1-C5 and exhibited weak activity, despite being sesqui-
terpene lactones. Furthermore, it can also be observed that the
most active compounds were those with the guaiane carbon
skeletons without the epoxy group, as present in EHP. Hence for
this evaluation, the epoxy group may not be necessary for this
activity as stated by Schmidt (2006), but instead could be exerting
a steric or polar hindrance. Through virtual screening, sesqui-
terpenoids from Chicorium intybus exerted anti-acetylcholinester-
ase activities (Rollinger et al., 2006; Rollinger et al., 2005). The
AChE inhibition of these compounds was conﬁrmed through an
activity-guided fractionation of the chicory root extract which led
to the isolation of two sesquiterpene lactones, 8-deoxylactucin and
lactucopicrin. These two guaiane-type sesquiterpenoids showed
signiﬁcant and dose-dependent inhibitory activity on AChE. Re-
cently, guaianolides obtained from Amberboa ramosa showed good
inhibitory activities against AChE and BChE. The authors indicated
that the effect of substituents at C-10 (Fig. 1., guaiane skeleton) is
more important for AChE inhibition (Ibrahim et al., 2013).
Previous studies have shown that PDA acts on the central
nervous system by exerting antidepressant-like effect in-vivo
(Goncalves et al., 2012) while ARD has previously been isolated
from Xylopia brasiliensis which is used in folk medicine as a se-
dative and analgesic (Moreira et al., 2003). Meanwhile, germa-
crane-type sesquiterpenoids have also been found to be effective
against AD. These compounds which were isolated from Valeriana
amurensis were investigated for their protective effect on PC 12
neuronal cells and they seem to afford protection against Aβ-in-
duced toxicity in PC 12 cells (Wang et al., 2012) Some sesqui-
terpenoids appear to show neuroprotective activities and can act
as pharmacological targets for neurodegenerative diseases like
Alzheimer and Parkinson (Chung et al., 2010).5. Conclusions
Sesquiterpenoids obtained from Hedyosmum brasiliense ex-
hibited important effects on the nervous system of mice. The
compounds studied here, exert nootropic effect inhibiting the
cognitive deﬁcits induced by Aβ1-42 and that may be potential
S.K.S. Amoah et al. / European Journal of Pharmacology 769 (2015) 195–202 201candidates for Alzheimer's disease therapy. These compounds
appear to have an effect on oxidative stress and thus enhance
memory in mice that received Aβ1-42 infusion. Unlike the re-
cognized mechanism of biological action of the sesquiterpene
lactones (Michael-type nucleophilic addition), the tested com-
pounds produced neuroprotective effects more related to the
presence of the ﬁve-membered guaiane ring than to the presence
of the lactone ring.Conﬂict of interest
The authors have declared that there is no conﬂict of interest.Acknowledgements
We gratefully acknowledge ﬁnancial support received from
CAPES (Scholarships - 4.100.10.100.44.P7), UNIVALI, CNPq (Grant
no. 481894/2009-8) and FAPESC (Grant no. 072009- UNIVERSAL)
(Brazil). The authors are grateful to Prof. Dr. Ademir Reis (De-
partamento de Botânica da UFSC, Brazil) for the identiﬁcation of
the species under study.
Maria Tereza Dalla Vecchia, Beatriz Pedrini and Gabriela Laz-
zarotto Carnhelutti thank UNIVALI for the fellowship support.References
Alikhani, N., Guo, L., Yan, S., Du, H., Pinho, C.M., Chen, J.X., Glaser, E., Yan, S.S., 2011.
Decreased proteolytic activity of the mitochondrial amyloid-beta degrading
enzyme, PreP peptidasome, in Alzheimer’s disease brain mitochondria. J. Alz-
heimers Dis. 27, 75–87.
Alonso, M., Bekinschtein, P., Cammarota, M., Vianna, M.R., Izquierdo, I., Medina, J.H.,
2005. Endogenous BDNF is required for long-term memory formation in the rat
parietal cortex. Learn. Mem. 12, 504–510.
Amoah, S.K.S., de Oliveira, F.L., da Cruz, A.C.H., de Souza, N.M., Campos, F.R., Barison,
A., Biavatti, M.W., 2013. Sesquiterpene lactones from the leaves of Hedyosmum
brasiliense (Chloranthaceae). Phytochemistry 87, 126–132.
Beutler, E., Duran, O., Kelley, B., 1963. Modiﬁed procedure for the estimation of
reduced glutathione. J. Lab. Clin. Med. 61, 882.
Blank, M., Dornelles, A.S., Werenicz, A., Velho, L.A., Pinto, D.F., Fedi, A.C., Schroder,
N., Roesler, R., 2014. Basolateral amygdala activity is required for enhancement
of memory consolidation produced by histone deacetylase inhibition in the
hippocampus. Neurobiol. Learn. Mem. 111, 1–8.
Blay, G., Bargues, V., Cardona, L., Garcia, B., Pedro, J.R., 2000. Stereoselective
synthesis of 7,11-guaien-8,12-olides from santonin. Synthesis of podoandin and
(þ)-zedolactone A. J. Org. Chem. 65, 6703–6707.
Chadwick, M., Trewin, H., Gawthrop, F., Wagstaff, C., 2013. Sesquiterpenoids lac-
tones: beneﬁts to plants and people. Int. J. Mol. Sci. 14, 12780–12805.
Chaturvedi, D., 2011. Sesquiterpene lactones: structural diversity and their biolo-
gical activities, In-Opportunity, Challanges and Scope of Natural Products in
Medicinal Chemistry. Research Signpost. Trivandrum, 313–334.
Chen, Q.F., Liu, Z.P., Wang, F.P., 2011. Natural sesquiterpenoids as cytotoxic antic-
ancer agents. Mini Rev. Med. Chem. 11, 1153–1164.
Chen, Z., Zhong, C., 2014. Oxidative stress in Alzheimer’s disease. Neurosci. Bull.,
1–11.
Cheng, G., Whitehead, S.N., Hachinski, V., Cechetto, D.F., 2006. Effects of pyrrolidine
dithiocarbamate on beta-amyloid (25-35)-induced inﬂammatory responses
and memory deﬁcits in the rat. Neurobiol. Dis. 23, 140–151.
Chung, I.M., Kim, E.H., Jeon, H.S., Moon, H.I., 2010. Protective effects of iso-
atriplicolide tiglate from Paulownia coreana against glutamate-induced neu-
rotoxicity in primary cultured rat cortical cells. Nat. Prod. Commun. 5, 851–852.
Di Stasi, L.C., Costa, M., Mendacolli, S.L.J., Kirizawa, M., Gomes, C., Trolin, G., 1988.
Screening in mice of some medicinal plants used for analgesic purposes in the
state of Sao Paulo. J. Ethnopharmacol. 24, 205–211.
Ding, F., Yao, J., Rettberg, J.R., Chen, S., Brinton, R.D., 2013. Early decline in glucose
transport and metabolism precedes shift to ketogenic system in female aging
and Alzheimer’s mouse brain: implication for bioenergetic intervention. Plos.
ONE 8, e79977.
Dringen, R., Gutterer, J.M., Hirrlinger, J., 2000. Glutathione metabolism in brain
metabolic interaction between astrocytes and neurons in the defense against
reactive oxygen species. Eur. J. Biochem. 267, 4912–4916.
Essa, M.M., Vijayan, R.K., Castellano-Gonzalez, G., Memon, M.A., Braidy, N., Guille-
min, G.J., 2012. Neuroprotective effect of natural products against Alzheimer’s
disease. Neurochem. Res. 37, 1829–1842.
Fang, L., Fang, X., Gou, S., Lupp, A., Lenhardt, I., Sun, Y., Huang, Z., Chen, Y., Zhang, Y.,Fleck, C., 2014. Design, synthesis and biological evaluation of D-ring opened
galantamine analogs as multifunctional anti-Alzheimer agents. Eur. J. Med.
Chem. 76, 376–386.
Furini, C., Myskiw, J., Schmidt, B., Marcondes, L., Izquierdo, I., 2014. D1 and D5
dopamine receptors participate on the consolidation of two different mem-
ories. Behav. Brain Res. 271, 212–217.
Gach, K., Dlugosz, A., Janecka, A., 2015. The role of oxidative stress in anticancer
activity of sesquiterpene lactones. Naunyn Schmiedebergs Arch. Pharmacol.
388, 477–486.
Gao, J., Inagaki, Y., Li, X., Kokudo, N., Tang, W., 2013. Research progress on natural
products from traditional Chinese medicine in treatment of Alzheimer’s dis-
ease. Drug. Discov. Ther. 7, 46–57.
Goncalves, A.E., Burger, C., Amoah, S.K., Tolardo, R., Biavatti, M.W., de Souza, M.M.,
2012. The antidepressant-like effect of Hedyosmum brasiliense and its sesqui-
terpene lactone, podoandin in mice: evidence for the involvement of adre-
nergic, dopaminergic and serotonergic systems. Eur. J. Pharmacol. 674,
307–314.
Gongadze, N., Antelava, N., Kezeli, T., Okudjava, M., Pachkoria, K., 2008. The me-
chanisms of neurodegenerative processes and current pharmacotherapy of
Alzheimer’s disease. Georgian Med. News, 44–48.
Hajimehdipoor, H., Mosaddegh, M., Naghibi, F., Haeri, A., Hamzeloo-Moghadam, M.,
2014. Natural sesquiterpene lactones as acetylcholinesterase inhibitors. Acad.
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